Chronic Obstructive Pulmonary Disease
Researchers predict that the number of COPD cases will increase by more than 150% from 2010 to 2030.
Endoscopic sinus surgery improved asthma quality of life and control in patients with uncontrolled asthma.
Exacerbations were associated with accelerated lung function loss in patients with established COPD.
COPD-related mortality was reduced by 12.3% between 2000 and 2014.
The combination may reduce the rate of moderate or severe exacerbations among COPD patients.
Clinician awareness of COPD treatment guidelines has increased since 2007.
Patients with a blood eosinophil count below 2% had a poor response to treatment with inhaled corticosteroids.
Potential effects of statin use as adjunct therapy in COPD patients is still widely debated.
For patients hospitalized with COPD, mortality and length of stay have decreased while financial burden has increased.
The COPD Assessment Test (CAT) can be used to distinguish between newly diagnosed patients, those with more exacerbations, and by gender.
Patients who are socioeconomically disadvantaged are more likely to continue smoking after a COPD diagnosis.
Older adults with depression are less likely to adhere to COPD maintenance medications regimens.
Patients with mild-to-moderate airflow limitations should be screened for COPD exacerbations.
Patients who complete pulmonary rehabilitation programs may experience short-term symptom reversal.
Many HIV-positive patients who meet the criteria for COPD are not receiving proper treatment.
Patients who participate in rehabilitation have a lower in-hospital mortality rate.
In early adulthood, 75% of participants showed decline in lung function or reduced lung growth.
Exacerbations were reduced in COPD patients with a history of at least 1 exacerbation in the past year.
Although COPD is the third leading cause of death in the US, patients often lack access to basic therapies and consistent care.
In patients with COPD, chronic renal failure is more likely and can be detected from decreased glomerular filtration rates.
The addition of tiotropium does not reduce COPD exacerbations.
The FDA has approved a long-acting dual bronchodilator, Bevespi Aerosphere, for the management of COPD.
The number of patients receiving all recommending pharmacologic therapies improved after the implementation of a computerized multidisciplinary order in patients' EHRs.
The USPSTF has released an updated recommendation statement that does not recommend screening asymptomatic adults for COPD.
Beta-blockers reduced the risk of COPD exacerbations between 21% and 55%.
Some variance is observed in outcomes for patients with COPD who are treated by NPs or PAs versus those treated by physicians.
mTOR inhibition via rapamycin restores corticosteroid sensitivity in patients with COPD.
Take caution when using oxygen therapy to treat patients with emphysema.
The risk was found to be even higher at 5 years after diagnosis
Opioids had no impact on exercise capacity, however.